Addition of DNA Profiles to FBI Database Expected to Increase Links of Potential Suspects to Crimes

CARLSBAD, Calif.–Applied Biosystems, part of Life Technologies Corporation (NASDAQ:LIFE) today announced that its AmpF?STR® MiniFiler™ PCR Amplification Kit has been approved for inclusion in the National DNA Index System (NDIS), a United States Federal Bureau of Investigation database that facilitates the electronic comparison and exchange of DNA profiles between participating local, county, state, and federal law enforcement agencies and forensic laboratories. The MiniFiler kit, designed to obtain DNA results from compromised or degraded samples, has proven its utility globally in a wide range of investigations, including cold cases, missing person cases, exonerations and historical and archeological cases.

“Some laboratories have already generated valuable data from unsolved crimes and have been waiting for this opportunity to compare it to the NDIS database. Ultimately, this approval will help solve more crimes, reopen unsolved cold cases, exonerate the wrongly accused and help identify missing persons.”

With the approval by the NDIS board, the MiniFiler kit will be more widely utilized by U.S. forensic laboratories, with data subsequently uploaded into NDIS, leveraging the power of the database to solve more criminal investigations. The NDIS database is a highly valued tool used by law enforcement professionals in order to compare genetic profile information related to crimes committed across the United States. Managed by the FBI as the nation’s forensic DNA database, the NDIS database currently contains more than 7 million profiles and has produced more than 98,000 matches between a DNA profile and the NDIS database, assisting in more than 97,000 criminal investigations.

“We expect that the NDIS approval of the MiniFiler kit, and subsequent uploading of MiniFiler data, will significantly enhance the ability to use results recovered from challenging evidence samples to link crime scenes with potential suspects and other crime scenes,” said Leonard Klevan, Ph.D., President of Human Identification at Life Technologies. “Some laboratories have already generated valuable data from unsolved crimes and have been waiting for this opportunity to compare it to the NDIS database. Ultimately, this approval will help solve more crimes, reopen unsolved cold cases, exonerate the wrongly accused and help identify missing persons.”

Introduced in 2007, the MiniFiler Kit is the world’s first commercially available reagent kit designed with miniSTR amplicons to increase the ability to obtain DNA results from compromised samples that previously would have yielded little to no genetic data.

About Life Technologies (www.lifetechnologies.com)

Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit our website: www.lifetechnologies.com. Follow Life Technologies on Twitter @LIFECorporation and on Facebook.

Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.